InterestingFACT
Bluelighter
- Joined
- Nov 18, 2013
- Messages
- 512
At least according to the paper I linked earlier, DOC (and most phenethylamines) is a full agonist at the inositol triphosphate pathway but a partial agonist at the arachidonic acid pathway of 5ht2a. What this means, exactly, is anyone's guess. David Nichols had a theory that the difference in activation of these two pathways explained the disparity between psychedelic and non-psychedelic 5ht2a agonists, but that theory has been largely discredited.I don't think DOC causes full agonism though either, or does it? I thought the reason that NBOMes were developed for (actual, legitimate) research purposes was because of their full agonism properties, which are not typically found. Or is it just because they're super selective?
I believe nbomes are full agonists at both pathways, and I believe that it's the arachidonic acid pathway which is most likely to lead to dangerous physiological effects. So it makes sense that DOC has a better safety profile. That being said, DOC is, to my knowledge, a higher affinity partial agonist at the arachidonic acid pathway than LSD or psilocin.
As for the nbomes. I think Nichols created them in an attempt to explore the SAR of the 5ht2a receptor pharmacophor. I'm not sure they really had a "purpose," per say. But I very well might be wrong about all that.